Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Breast Cancer

Free Subscription Articles published in Int J Oncol Retrieve available abstracts of 24 articles: HTML format

Single Articles

March 2026
1. ZHANG N, Wang T, Bai B, Zhang X, et al
   PTPN18 functions as a tumor suppressor in breast cancer by negatively regulating cyclin E.
   Int J Oncol. 2026;68:30.
   PubMed     Abstract available
   
   
   
2. VIEDMA-RODRIGUEZ R, Baiza-Gutman LA, Garcia-Carranca A, Moreno-Fierros L, et al
   [Retracted] Suppression of the death gene BIK is a critical factor for resistance to tamoxifen in MCF?7 breast cancer cells.
   Int J Oncol. 2026;68:29.
   PubMed     Abstract available
   
   
   January 2026
3. MALLA RR, Raghu H, Rao JS
   [Expression of Concern] Regulation of NADPH oxidase (Nox2) by lipid rafts in breast carcinoma cells.
   Int J Oncol. 2026;68:1.
   PubMed     Abstract available
   
   
   
4. LI K, Wei L, Huang Y, Wu Y, et al
   [Expression of Concern] Leptin promotes breast cancer cell migration and invasion via IL?18 expression and secretion.
   Int J Oncol. 2026;68:3.
   PubMed     Abstract available
   
   
   
5. LUO J, Yang Y, Cheng L, Cheng F, et al
   Discovery of the late autophagy inhibitor FZU?0045?053 and its anti?breast cancer and immunomodulatory effects.
   Int J Oncol. 2026;68:10.
   PubMed     Abstract available
   
   
   
6. LI F, Gao Z
   Obesity, chronic breast inflammation and carcinogenesis: Molecular pathways and clinical implications (Review).
   Int J Oncol. 2026;68:12.
   PubMed     Abstract available
   
   
   December 2025
7. HUA K, Jin J, Zhao J, Song J, et al
   [Expression of Concern] miR?135b, upregulated in breast cancer, promotes cell growth and disrupts the cell cycle by regulating LATS2.
   Int J Oncol. 2025;67:96.
   PubMed     Abstract available
   
   
   
8. GELSOMINO L, Del Console P, Murfuni MS, Gaspari M, et al
   Adipocyte?derived extracellular vesicles sustain mitochondrial metabolism in breast cancer cells: New insights into the cross?talk between cancer cells and the tumor microenvironment.
   Int J Oncol. 2025;67:100.
   PubMed     Abstract available
   
   
   
9. JIN ML, Park SY, Kim YH, Park G, et al
   [Expression of Concern] Halofuginone induces the apoptosis of breast cancer cells and inhibits migration via downregulation of matrix metalloproteinase?9.
   Int J Oncol. 2025;67:106.
   PubMed     Abstract available
   
   
   November 2025
10. ZOU X, Li S, Huang S, Niu R, et al
    Harnessing TP73?targeted nintedanib: A novel strategy to halt triple?negative breast cancer via p53?PPARalpha/PI3K?Akt pathway suppression.
    Int J Oncol. 2025;67:88.
    PubMed     Abstract available
    
    
    
11. HUANG X, Luo W, Liu W, Liu X, et al
    Progerin regulates actin cytoskeletal remodeling and inhibits EMT and metastasis in triple?negative breast cancer cells.
    Int J Oncol. 2025;67:92.
    PubMed     Abstract available
    
    
    August 2025
12. KAUSAR MA, Alshammari KF, Alenazi F, Anwar S, et al
    RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review).
    Int J Oncol. 2025;67:65.
    PubMed     Abstract available
    
    
    
13. CHUNG SS, Giehl N, Wu Y, Vadgama JV, et al
    [Corrigendum] STAT3 activation in HER2?overexpressing breast cancer promotes epithelial?mesenchymal transition and cancer stem cell traits.
    Int J Oncol. 2025;67:69.
    PubMed     Abstract available
    
    
    July 2025
14. PARK AY, Kim JH, Lee S, Kim HS, et al
    Impact of PD?L1 upregulation on immune checkpoint inhibitor efficacy in triple?negative breast cancer using a 4T1 murine model.
    Int J Oncol. 2025;67:54.
    PubMed     Abstract available
    
    
    June 2025
15. ZHANG X, Zhao X, Shao S, Zuo X, et al
    [Retracted] Notch1 induces epithelial?mesenchymal transition and the cancer stem cell phenotype in breast cancer cells and STAT3 plays a key role.
    Int J Oncol. 2025;66:46.
    PubMed     Abstract available
    
    
    
16. KIM ES
    Molecular targets and therapies associated with poor prognosis of triple?negative breast cancer (Review).
    Int J Oncol. 2025;66:52.
    PubMed     Abstract available
    
    
    May 2025
17. SUN MX, Zhu HC, Yu Y, Yao Y, et al
    Role of the Wnt signaling pathway in the complex microenvironment of breast cancer and prospects for therapeutic potential (Review).
    Int J Oncol. 2025;66:36.
    PubMed     Abstract available
    
    
    
18. GIL EY, Jo UH, Jeong H, Whang YM, et al
    [Retracted] Promoter methylation of RASSF1A modulates the effect of the microtubule?targeting agent docetaxel in breast cancer.
    Int J Oncol. 2025;66:39.
    PubMed     Abstract available
    
    
    January 2025
19. LEE WX, Yeo BS, Mahmud R, Tan GC, et al
    MicroRNAs and their role in breast cancer metabolism (Review).
    Int J Oncol. 2025;66:7.
    PubMed     Abstract available
    
    
    October 2024
20. SOLEK J, Braun M, Sadej R, Romanska HM, et al
    FGFR?related phenotypic and functional profile of CAFs in prognostication of breast cancer (Review).
    Int J Oncol. 2024;65:94.
    PubMed     Abstract available
    
    
    September 2024
21. YANG Y, Gao F, Ren L, Ren N, et al
    Functions and mechanisms of RNA m(6)A regulators in breast cancer (Review).
    Int J Oncol. 2024;65:86.
    PubMed     Abstract available
    
    
    
22. FU Z, Song P, Li D, Yi C, et al
    [Corrigendum] Cancer?associated fibroblasts from invasive breast cancer have an attenuated capacity to secrete collagens.
    Int J Oncol. 2024;65:87.
    PubMed     Abstract available
    
    
    May 2024
23. AI L, Yi N, Qiu C, Huang W, et al
    Revolutionizing breast cancer treatment: Harnessing the related mechanisms and drugs for regulated cell death (Review).
    Int J Oncol. 2024;64:46.
    PubMed     Abstract available
    
    
    April 2024
24. MBUGUA RW, Takano A, Tsevegjav B, Yokose T, et al
    Characterization of KIF20B as a novel prognostic biomarker and therapeutic target for breast cancer.
    Int J Oncol. 2024;64:43.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.